Boehringer Ingelheim announces winners of BVDzero Scholarship Programme

Ingelheim, Germany, 17 June 2019 – The BVDzero Committee, consisting of industry experts from various countries, in collaboration with a representative of the World Association for Buiatrics, identified outstanding 12 veterinary students from around the world who can help address the ever-changing industry and the health, food, and welfare needs of the veterinary community.

The BVDzero Committee

Initially, awards were to identify top 10 students. However, due to a very high standard of submissions, the Committee took a decision to select 12 outstanding students for the scholarships of 1,000 euros awarded to each student to cover their transport to World Buiatrics Congress 2020 in Madrid. Each scholarship winner will also receive free registration and accommodation at the Congress, compliments of Boehringer Ingelheim.

The Congress represents a top industry event to network and learn where the students will have a unique opportunity to improve their veterinary knowledge about cattle medicine, meet top subject matter experts and key opinion leaders as well the Boehringer Ingelheim Animal Health Business Unit cattle team.

The 12 BVDzero Scholarship Programme winners are as follows:

• Allison Hale, US
• Amy Birch, Australia
• Bruna Mendes, Brazil
• Eugenia Ishaku, Nigeria
• Jessie Hesseling, The Netherlands
• Jia Cheng, China
• Lovina Ikwe, Nigeria
• Mariel Burquez, Mexico
• Samuel Kalis, US
• Savannah Basham, US
• Tahia Logna, Bangladesh
• William Philips, UK

“We were delighted to see such huge interest by students from around the world. We received 454 submissions in total. Through this initiative, we want to draw attention to and create awareness of BVD by veterinary students. On top of it, our objective is to make connections with those who may wish to build their career with Boehringer Ingelheim, joining us in our effort to create the future of animal health,” shared Serkan Erkovan, Senior Global Manager for Ruminant Business at Boehringer Ingelheim.

Congratulations to all the winners!

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview

World Association for Buiatrics

The Association strives to promote goodwill and knowledge transfer within the international veterinary community by exchanging and discussing scientific, cultural and personal experiences within the framework of the World Association for Buiatrics.

More information can be found on: http://buiatrics.com/.

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.